News about "triple-negative breast cancer "

EMA Recommends Approval of Datroway for First-Line Treatment of Triple-Negative Breast Cancer

AstraZeneca and Daiichi Sankyo have received a positive recommendation from the European Medicines Agency's CHMP for Datroway as a first-line treatment for unresectable or metastatic triple-negative breast cancer in patients who are not eligible for immunotherapy, supported by Phase 3 trial results demonstrating improved survival and disease control.

Triple-Negative Breast Cancer | 29/06/2026 | By News Bureau

US FDA Approves KEYTRUDA and KEYTRUDA QLEX, Each with Trodelvy

The US Food and Drug Administration (FDA) has approved KEYTRUDA and KEYTRUDA QLEX in combination with Trodelvy as first-line treatment for adults with PD-L1-positive (CPS ≥10) advanced Triple-Negative Breast Cancer (TNBC).

Triple Negative Breast Cancer | 26/06/2026 | By News Bureau |  183

European Commission Approves Gilead's Trodelvy as First-Line Treatment for Metastatic Triple-Negative Breast Cancer

The European Commission has approved Trodelvy for first-line treatment of unresectable or metastatic triple-negative breast cancer, offering a new therapeutic option for patients with one of the most aggressive forms of breast cancer.

Triple-Negative Breast Cancer | 25/06/2026 | By News Bureau

FDA Expands Approval of Agilent's PD-L1 Diagnostic Test on Dako Omnis Platform for Four Additional Cancer Types

Agilent Technologies has received FDA approval to expand the use of its PD-L1 IHC 22C3 pharmDx test on the Dako Omnis platform, broadening access to PD-L1 testing for four additional tumour types and supporting streamlined pathology laboratory operations.

Triple-Negative Breast Cancer | 05/06/2026 | By News Bureau |  152

CStone's CS2009 Secures U.S. FDA IND Clearance for Phase II Trial in Advanced Solid Tumours

CStone Pharmaceuticals has received U.S. FDA IND clearance to begin a Phase II trial of its trispecific antibody CS2009 for advanced solid tumours, advancing its global immunotherapy development programme.

Triple-Negative Breast Cancer | 16/02/2026 | By News Bureau |  192

Daiichi Sankyo Submits sNDA in Japan for Datroway in First-Line Metastatic TNBC

Daiichi Sankyo files supplemental application in Japan for Datroway as a first-line treatment for metastatic triple negative breast cancer based on phase III trial data.

Triple Negative Breast Cancer | 13/02/2026 | By News Bureau |  210

AstraZeneca and Daiichi Sankyo's Datroway Receives FDA Priority Review for First-Line Metastatic TNBC Treatment

The FDA has granted Priority Review to Datroway for first-line treatment of metastatic triple-negative breast cancer patients ineligible for immunotherapy, with a regulatory decision expected in Q2 2026.

Triple-negative Breast Cancer | 04/02/2026 | By News Bureau |  185

Common Cholesterol Drug Shows Promise Against Drug-Resistant Breast Cancer

Korea University researchers show the cholesterol drug inhibits Mcl-1, suppresses metastasis, and restores chemotherapy sensitivity in preclinical models of aggressive TNBC.

Triple-negative Breast Cancer | 08/01/2026 | By News Bureau |  313

Mabwell Gets NMPA Approval for Clinical Trial of Nectin-4 Targeting ADC in TNBC

Mabwell has announced that its novel Nectin-4 targeting ADC has been approved by the NMPA to enter Phase II clinical trial as monotherapy or in combination with a PD-1 inhibitor for the treatment of triple-negative breast cancer (TNBC).

Triple-negative Breast Cancer | 16/07/2024 | By Aishwarya |  284